 The study design includes up to a 10-week wk Screening 2 wksBaseline 8 wks Phase, a Titration Phase 2 wks, Dose-Optimization Phase 8 wks, Maintenance Phase 8 wks, and TaperFollow-Up Phase 3 wks. The total duration of the study for each subject will be approximately 31 wks, and at minimum approximately 27 wks if subjects provide reliable 28-day retrospective seizure data. 